Cerus (NASDAQ:CERS) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Cerus Co. (NASDAQ:CERSGet Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.89 and traded as high as $2.07. Cerus shares last traded at $1.98, with a volume of 1,200,281 shares.

Wall Street Analysts Forecast Growth

Separately, Stifel Nicolaus lowered their price target on shares of Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, October 17th.

Get Our Latest Report on CERS

Cerus Stock Up 2.1 %

The stock has a 50 day moving average price of $1.75 and a 200-day moving average price of $1.89. The stock has a market capitalization of $367.71 million, a P/E ratio of -18.00 and a beta of 1.27. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92.

Cerus (NASDAQ:CERSGet Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%. The business had revenue of $46.02 million during the quarter, compared to analyst estimates of $44.10 million. During the same period last year, the business posted ($0.03) earnings per share. As a group, research analysts expect that Cerus Co. will post -0.11 EPS for the current fiscal year.

Insider Activity at Cerus

In related news, Director Eric Bjerkholt sold 20,000 shares of Cerus stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total transaction of $35,600.00. Following the transaction, the director now owns 162,133 shares in the company, valued at approximately $288,596.74. The trade was a 10.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.40% of the stock is owned by insiders.

Institutional Trading of Cerus

Large investors have recently added to or reduced their stakes in the company. R Squared Ltd purchased a new position in Cerus during the 4th quarter valued at $29,000. Creative Planning increased its position in Cerus by 51.3% during the 3rd quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 8,411 shares in the last quarter. PCA Investment Advisory Services Inc. acquired a new position in Cerus during the 4th quarter valued at about $46,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in Cerus by 38.4% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 9,737 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Cerus during the 3rd quarter valued at about $71,000. Institutional investors own 78.37% of the company’s stock.

About Cerus

(Get Free Report)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Recommended Stories

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.